Bortezomib in mantle cell lymphoma

Future Oncol. 2008 Apr;4(2):149-68. doi: 10.2217/14796694.4.2.149.


Mantle cell lymphoma (MCL) represents 6% of non-Hodgkin lymphomas, but is one of the most active fields of clinical investigation. Unfortunately, there is still no standard or curative therapy in MCL. Front-line therapy appears to benefit from intensification either through high-dose therapy with stem cell transplant consolidation or dose-intense chemotherapy with hyperfractionated cyclophosphamide, vincristine, adriamycin/doxorubicin and dexamethasone/rituximab. Most patients still relapse and a multitude of novel agents are currently being tested in this setting, including proteasome inhibitors with bortezomib (the first of its class and the first US FDA-approved drug for MCL), mTOR inhibitors, Bcl-2 inhibitors, antiangiogenesis agents and histone deacetylase inhibitors among others. An obvious effort is needed to enroll patients on clinical trials, the design of which might benefit from pharmacogenomics and a better understanding of MCL biology and its diversity.

Publication types

  • Review

MeSH terms

  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / pharmacology
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Clinical Trials as Topic
  • Female
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy*
  • Male
  • Middle Aged
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use
  • Pyrazines / pharmacology
  • Pyrazines / therapeutic use*
  • Recurrence
  • Treatment Outcome


  • Antineoplastic Agents
  • Boronic Acids
  • Protease Inhibitors
  • Pyrazines
  • Bortezomib